FINHUB Insights

EW · Q2 FY26 · Apr 1 – Jun 30, 2026

Edwards Lifesciences Q2 FY26: where the revenue came from and where it went

Edwards Lifesciences Q2 FY26: revenue $1.7B (+14% year over year). Net profit $0.24B. Largest cohort Aortic valve replacement $1.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Aug 4, 2026 10-Q
Sankey diagram of Edwards Lifesciences's income statement for Q2 FY26: revenue of $1.74 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.74B +14% year over year
Gross profit$1.35B 77% margin
Operating profit$0.51B 29% margin
Net profit$0.24B 14% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 1.74 100% +14%
Aortic valve replacement 1.26 72% +11%
Surgical 0.28 16% +6%
Transcatheter mitral 0.20 11% +48%
Cost of revenue−0.3923%
Gross profit1.3577% margin+0pp
R&D−0.2816%−2pp
SG&A−0.5632%−1pp
Operating profit0.5129% margin+3pp
Tax−0.27
Net profit0.2414%−8pp
Filing on EDGAR More quarters of EW

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.